Dr. Hui Chen has more than 10 years of experience in analytical development and quality control for biologics and cell and gene therapy. She has experience with new drug and biosimilar application procedures to authorities (U.S. FDA, EMA, and CDE). She got her Ph.D. in pharmaceutics at KU Leuven, Belgium, and obtained her MBA at Rotterdam School of Management, Erasmus University, the Netherlands, and an exchange MBA at Duke University. At Porton Advanced, Dr. Chen leads the gene therapy department and the analytical development department as Vice President.
.svg)
